title: Efficacy and tolerability of the renin inhibitor Ro 42-5892 in patients with hypertension.
abstract: The efficacy of multiple oral administration of the renin inhibitor Ro 42-5892 [(S)-alpha-](t-butylsulfonyl)-methyl]hydrocinnamamido]-N-[1S , 2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-imi dazole-4- propionamide] was studied. Forty-nine patients with moderate essential hypertension were randomly assigned to three groups that entered an 8-day double-blind oral treatment period: daily administration of placebo (group A), 300 mg Ro 42-5892 (group B), or 600 mg Ro 42-5892 (group C). Four hours after the last oral drug intake, placebo was administered intravenously to subjects in group A and 100 mg Ro 42-5892 was administered intravenously to subjects in groups B and C. Sitting systolic and diastolic blood pressures were measured on days 1 and 8 with a blood pressure device. On day 1, systolic blood pressure maximally decreased by 13.3 +/- 9.3, 20.2 +/- 11.2, and 24.1 +/- 11.3 mm Hg in groups A, B, and C, respectively (mean +/- SD; p < 0.01 for group A versus group C). Diastolic blood pressure maximally decreased 9.4 +/- 5.7, 13.9 +/- 8.7, and 11.8 +/- 5.7 mm Hg (difference not significant). On day 8, systolic blood pressure maximally decreased 19.5 +/- 16.5, 26.5 +/- 17.4, and 30.5 +/- 18.4 mm Hg and diastolic blood pressure maximally decreased 14.8 +/- 5.0, 16.2 +/- 9.0, and 17.9 +/- 12.7 mm Hg (difference not significant) compared with pretreatment values. Intravenous drug administration did not further reduce blood pressure, suggesting that the mode of action and not the low bioavailability was the limiting factor for the low efficacy.
authors.affiliation: Department of Medicine, University Hospital Nijmegen, The Netherlands.
authors.forename: G A
authors.initials: GA
authors.lastname: Rongen
authors.forename: J W
authors.initials: JW
authors.lastname: Lenders
authors.forename: C H
authors.initials: CH
authors.lastname: Kleinbloesem
authors.forename: C
authors.initials: C
authors.lastname: Weber
authors.forename: H
authors.initials: H
authors.lastname: Welker
authors.forename: E
authors.initials: E
authors.lastname: Fahrner
authors.forename: H
authors.initials: H
authors.lastname: Pozenel
authors.forename: A J
authors.initials: AJ
authors.lastname: Woittiez
authors.forename: G
authors.initials: G
authors.lastname: Haug
authors.forename: M S
authors.initials: MS
authors.lastname: Buchmann
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D000092502:Renin Inhibitors
chemical_list: D000959:Antihypertensive Agents; D007093:Imidazoles; D000092502:Renin Inhibitors; C065581:remikiren